Research progress of adjuvant therapy based on transcatheter arterial chemoembolization after radical resection of hepatocellular carcinoma
10.3760/cma.j.cn115396-20240418-00117
- VernacularTitle:肝细胞癌根治术后辅助性经导管动脉化疗栓塞术治疗的研究进展
- Author:
Jiahui ZHOU
1
;
Gege CHENG
;
Shasha PENG
Author Information
1. 武汉科技大学医学部医学院，武汉 430000
- Keywords:
Carcinoma, hepatocellular;
Recurrence;
Antineoplastic combined chemotherapy protocols;
Transcatheter arterial chemoembolization
- From:
International Journal of Surgery
2024;51(8):560-565
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive tract in the world, with high malignancy, strong invasion, high postoperative recurrence rate and low overall survival rate. Transcatheter arterial chemoembolization (TACE) has been recognized as one of the most commonly used local treatment methods for liver cancer. For high risk of recurrence (such as the diameter of the tumor larger (> 5 cm in diameter), preoperative AFP levels, and large vascular invasion, with microvascular invasion, etc.) after radical resection of liver cancer patients, Postoperative adjuvant transarterial chemoembolization (PA-TACE) can bring benefits to the prognosis of patients with liver cancer.At the same time, TACE combined with other therapies such as antiviral therapy, molecular targeted therapy, immunotherapy, ablative radiation therapy and traditional Chinese medicine therapy have shown good efficacy. This article reviews the research progress of adjuvant therapy based on PA-TACE after radical resection of hepatocellular carcinoma.
